Omission of breast surgery after neoadjuvant systemic therapy (NST) in select patients with invasive breast cancer may be feasible, according to a study published online March 28 in the Journal of the ...

They found that by targeting and silencing a specific gene expression, ERBB2, the chances of stopping tumor growth significantly increased. ERBB2 is one of the many genes that regulate cell growth.

Each ERBB receptor has distinct locations and numbers of tyrosine phosphorylation sites on its C-terminal tails; there are twelve on ERBB1, six on ERBB2, and eleven on ERBB3 (Jones et al.